RecruitingNot ApplicableNCT05882253
Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to Enhance MRI Diagnostic Capabilities in Prostate Cancer
Sponsor
University of California, San Diego
Enrollment
225 participants
Start Date
Dec 4, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
Eligibility
Sex: MALE
Inclusion Criteria2
- Selected to undergo an MRI-fusion prostate needle biopsy of the prostate.
- Able to provide informed consent
Exclusion Criteria7
- prior diagnosis of prostate cancer (Grade Group \>1)
- metastatic prostate cancer
- prior prostate cancer treatment
- contraindication to prostate biopsy (e.g., on anticoagulation that cannot be safely discontinued)
- inability to undergo MRI (e.g., too large to be accommodated in a scanner or with an implant incompatible with MRI).
- Bilateral hip replacement
- Unable to provide informed consent.
Interventions
OTHERRestricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)
An advanced imaging software that supports improved prostate cancer detection and diagnosis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05882253
Related Trials
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT057519412 locations